Related Experiment Video

Updated: Apr 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Kazuhiro Asami1, Shinji Atagi1

  • 1Kazuhiro Asami, Shinji Atagi, Department of Clinical Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai City, Osaka 591-8555, Japan.

World Journal of Clinical Oncology
|October 11, 2014
PubMed

Insights

First-generation EGFR-TKIs benefit advanced NSCLC with EGFR mutations but resistance develops. Second-generation agents offer new strategies for overcoming resistance in non-small cell lung cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • First-generation EGFR-TKIs (gefitinib, erlotinib) are effective for advanced NSCLC with EGFR mutations (e.g., exon 19 deletion, L858R).
  • These reversible inhibitors provide significant response and survival benefits.
  • Acquired resistance limits the long-term efficacy of first-generation EGFR-TKIs in all responders.

Purpose of the Study:

  • To review novel therapeutic strategies for EGFR-mutated advanced non-small cell lung cancer (NSCLC).
  • To discuss the role of first- and second-generation EGFR-TKIs in managing NSCLC.
  • To explore treatment approaches for patients who develop resistance to initial EGFR-TKI therapy.

Main Methods:

  • Literature review of studies on EGFR-TKIs in advanced NSCLC.
  • Analysis of clinical trial data for first- and second-generation EGFR-TKIs.
  • Discussion of resistance mechanisms and emerging therapeutic strategies.

Main Results:

  • First-generation EGFR-TKIs demonstrate efficacy in specific EGFR-mutated NSCLC populations.
  • Acquired resistance is an inevitable challenge for patients treated with first-generation EGFR-TKIs.
  • Second-generation EGFR-targeting agents show promise for improving outcomes and overcoming resistance.

Conclusions:

  • EGFR-TKIs represent a cornerstone of targeted therapy for EGFR-mutated NSCLC.
  • Understanding and overcoming acquired resistance is critical for improving patient survival.
  • Second-generation EGFR-TKIs offer a promising avenue for further therapeutic advancement in NSCLC management.
Keywords:
Epidermal growth factor receptor mutationEpidermal growth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerSecondary resistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
681
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.2K